AstraZeneca PLC released its flu vaccine nasal spray for at-home use on Friday, an option that comes at a contentious time for vaccine access in the US.
FluMist Home is the same product as the pharmaceutical company’s seasonal influenza vaccine spray, which has been offered by clinicians for the past two decades. FluMist Home received approval for patients ages 2 and up from the US Food and Drug Administration last fall.